

## Special Issue

# Overcoming Drug Resistance: Precision Medicine Drug Therapy

### Message from the Guest Editors

This Special Issue of *Cancers* aims to highlight recent progress in understanding the molecular and cellular mechanisms of drug resistance, and how precision medicine approaches—such as biomarker-guided therapies, genomic profiling, combination treatments, and novel drug delivery systems—can be leveraged to overcome these challenges. We also welcome studies grounded in evidence-based medicine, including clinical trials, real-world data analyses, systematic reviews, and meta-analyses, which not only support the translation of precision strategies into practice but also provide critical evidence and guidance for clinical decision-making. Furthermore, this Special Issue encourages research on how precision medicine drug therapies can help prevent cancer relapse and reduce treatment-related complications. By bringing together contributions from diverse disciplines, this Special Issue aims to deepen our understanding of drug resistance in both solid tumors and hematologic malignancies, and to advance the development of more effective, personalized cancer therapies.

---

### Guest Editors

Dr. Chenyu Sun  
Dr. Yuting Huang  
Dr. Raveena Manem

---

### Deadline for manuscript submissions

31 October 2026



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/255782](https://mdpi.com/si/255782)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)